argenx SE (ARGX)

Market Cap	37.59B
Revenue (ttm)	1.91B
Net Income (ttm)	-40.29M
Shares Out	60.09M
EPS (ttm)	-0.68
PE Ratio	n/a
Forward PE	93.13
Dividend	n/a
Ex-Dividend Date	n/a

Volume	11,514
Open	623.20
Previous Close	626.03
Day's Range	621.65 - 623.20
52-Week Range	349.86 - 644.97
Beta	0.27
Analysts	Strong Buy
Price Target	634.50 (+2.01%)
Earnings Date	Oct 31, 2024

About ARGX

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren’s syndrome, post-covid postural orthostatic tachycardia syndrome, ...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: May 18, 2017
• Employees: 1,148
• Stock Exchange: NASDAQ
• Ticker Symbol: ARGX
• Website: https://www.argenx.com

Financial Performance

In 2023, argenx SE's revenue was $1.27 billion, an increase of 187.66% compared to the previous year's $441.01 million. Losses were -$295.05 million, -58.42% less than in 2022.

Analyst Forecast

According to 20 analysts, the average rating for ARGX stock is "Strong Buy." The 12-month stock price forecast is $634.5, which is an increase of 2.01% from the latest price.

Price Target

$634.5

(2.01% upside)

Analyst Consensus: Strong Buy